Back

Solution Seekers

Regular Users

Current states

Desired states

Communication objectives

target

Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered

  2. ULIS III real-world data show significantly longer intervals between Dysport® injections compared to other BoNT-As in upper limb spasticity, supporting fewer clinic visits and streamlined patient management.

  3. AboLiSh study shows a mean reinjection interval of approximately 18 weeks in ambulatory lower limb spasticity, enabling efficient scheduling and cumulative functional gains over treatment cycles.

Main key supportive study :

  • High amount of neurotoxin: . Field M, et al. Toxins. 2018;10:535
  • ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • AboLiSh : Esquenazi A et al., Arch Phys Med Rehabil. 2024.

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar 
  • Jacinto reflection 
  • VAE to Ipsen Academy (to come)
  • VAE on duration of response (to come)

Communication objective associated: Demonstrate Dysport® benefits and applicability across patient types

  1. Dysport® contains the highest active neurotoxin content per licensed dose among BoNT-As, supporting effective treatment across a wide range of spasticity cases.
  2. Dysport® has a dose-response effect
  3. Flexible dosing allow clinicians to quickly tailor Dysport® treatment to each patient’s needs
  4. Recommended doses for upper / lower limb muscles

Main key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253
  • Amount of neurotoxins: Field M, et al. Toxins. 2018;10:535

Key material:

  • CLM presentation
  • Dosing app

Digital material for follow up:

  • Dosing app guide (to come)

Communication objective associated: Demonstrate the benefit of partnering with IPSEN to improve clinic efficiency

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation

Digital material for follow up

  • Invitation to (inter)national training